anti-Prekallikrein (PK) Antibodies

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Additionally we are shipping Prekallikrein Kits (7) and Prekallikrein Proteins (3) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
PK 354 P07288
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-Prekallikrein Antibodies at

Showing 10 out of 24 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Rabbit Un-conjugated ICC, IHC, WB DAB staining on IHC-P; Samples: Human Stomach cancer Tissue 100 μg Log in to see 13 to 16 Days
Human Rabbit Un-conjugated IF/ICC, IHC, IP, WB Western blot analysis of the recombinant protein. IHC-P analysis of Human Stomach cancer Tissue, with DAB staining. 100 μg Log in to see 11 to 18 Days
Human Mouse Un-conjugated ELISA (Capture), ELISA, WB   1 mL Log in to see 2 to 3 Days
Human Mouse Un-conjugated ELISA, WB   0.2 mg Log in to see 3 to 4 Days
Human Goat Un-conjugated ID, IEP   1 mL Log in to see 5 to 7 Days
Human Goat Un-conjugated ELISA   1 mL Log in to see 11 to 16 Days
Human Rabbit PE FACS, ICC, IF, IHC   150 μg Log in to see 2 to 3 Days
Human Rabbit FITC FACS, ICC, IF, IHC   150 μg Log in to see 2 to 3 Days
Human Rabbit APC FACS, ICC, IF, IHC   150 μg Log in to see 2 to 3 Days
Human Rabbit PerCP FACS   150 μg Log in to see 2 to 3 Days

More Antibodies against Prekallikrein Interaction Partners

Human Prekallikrein (PK) interaction partners

  1. Five single-nucleotide polymorphisms, rs266881 (OR = 2.92, P < 0.0001), rs174776 (OR = 1.91, P < 0.0001), rs266875 (OR = 1.44, P = 0.016), rs35192866 (OR = 4.48, P = 0.025) and rs1810020 (OR = 2.08, P = 0.034) correlated with an increased risk of male infertility. On the other hand, c.206 + 235 T > C, was more freuqent in the control group, showing protective association.

  2. In advanced prostate cancer with PSA levels >1000 ng/mL, sufficient PSA-A2M is present in circulation to produce enzymatic activity against circulating small peptide hormones.

  3. The aim of the study was to examine treatment patterns/outcomes with abiraterone (abi)/enzalutamide (enza) throughout PSA progression and near the end of life...abiraterone (abi)/enzalutamide are frequently discontinued for PSA progression alone and continued at end of life . The clinical benefit of these practices warrants additional study.

  4. The functional role of glycosylation in prostate-specific KLK3 could pave the way to a deeper understanding of their biology and to medical applications.

  5. These results shed a light on the genetic background of Benign prostatic hyperplasia and associated lower urinary tract symptoms and its substantial influence on PSA levels.

  6. Studies indicate that ghgh level of gamma-seminoprotein (gama-SM)/Prostate-Specific Antigen (PSA) could be detected in the blood [Review].

  7. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.

  8. Men with mild to no lower urinary tract symptoms (LUTS) but increased baseline PSA are at increased risk of developing incident LUTS presumed due to benign prostatic hyperplasia

  9. PSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer.

  10. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 mug/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 mug/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.

  11. PSA was the only independent predictor of extensive lymph node invasion and could be an important preoperative factor for stratifying high-risk patients.

  12. ue to the biocompatibility, multivalency, stability, and high structural homogeneity, the t-PSA-specific landscape phage demonstrates as a novel specific interface in biosensors.

  13. Based on the target-induced catalytic hairpin assembly and bimetallic catalyst, the enzyme-free recycling amplification strategy for sensitive detection of prostate specific antigen (PSA) has been designed

  14. The prepared biosensor can assay from 0 to 500ng/mL of prostate specific antigen (PSA) level within 2h with the detection limit of 1.18ng/mL by the measurement of resistance change. The resistance change was caused by site selective interaction between PSA and PSA-antigen with an inexpensive bench top digital multimeter (5 1/2 digits)

  15. he superwettable f-PSA microchip can accurately detect human serum samples with excellent correlations with chemiluminescence immunoassay in the clinic, demonstrating its great potential as a sensitive and reliable sensing platform for biological analysis and clinical diagnosis.

  16. The 12-week PSA response rate was 88% (22/25) and 22% (4/18), median time to PSA progression was 18.2 months [95% confidence interval (CI), 8.3 months-not reached) and 3.7 months (95% CI, 2.8-5.6 months), and median time on treatment 21 months (range, 2.6-37.5) and 4.9 months (range, 1.3-23.2), for the AAP-naive and post-AAP cohorts, respectively.

  17. The results support that u-PSA provides useful information for predicting predicting biochemical recurrence after radical prostatectomy . This can be beneficial to avoid unnecessary adjuvant treatments or to start them earlier for selected patients

  18. this meta-analysis suggests that PSA -158G/A polymorphism may be a protecting factor against BPH in Caucasian populations, but it may enhance the disease risk in Asians.

  19. Developed risk assessment models for North Chinese patients with 4-50 ng/mL PSA to reduce unnecessary prostate biopsies and increase the detection rate of prostate cancer.

  20. Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course.

Prekallikrein (PK) Antigen Profile

Protein Summary

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.

Gene names and symbols associated with anti-Prekallikrein (PK) Antibodies

  • kallikrein related peptidase 3 (KLK3) antibody
  • APS antibody
  • hK3 antibody
  • KLK2A1 antibody
  • PSA antibody

Protein level used designations for anti-Prekallikrein (PK) Antibodies

P-30 antigen , gamma-seminoprotein , kallikrein-3 , prostate specific antigen , prostate-specific antigen , semenogelase , seminin

354 Homo sapiens
Selected quality suppliers for anti-Prekallikrein (PK) Antibodies
Did you look for something else?